Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Vital Laboratories Pvt Ltd Plant II
WARNING LETTER
•Vital Laboratories Pvt Ltd Plant II•April 6, 2017

Vital Laboratories Pvt Ltd Plant II – FDA Warning Letter, Apr 6, 2017

Record Details

The FDA inspected Vital Laboratories Private Limited Plant-II in Vapi, Gujarat, from April 3-6, 2017, identifying significant deviations from current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (API), rendering them adulterated under 21 U.S.C. 351(a)(2)(B). The firm's April 27, 2017 response was deemed inadequate. Key violations included the failure to report, evaluate, and investigate production deviations; inadequate documentation of critical batch production steps with proper signatures; failure to adequately investigate and document out-of-specification (OOS) results and implement corrective actions; and the quality unit's failure to adequately perform annual product reviews (APR), including repeat errors. The letter highlighted repeated CGMP deviations across the company's network, indicating inadequate executive management oversight. The FDA strongly recommended engaging a qualified CGMP consultant. Vital Laboratories must conduct retrospective reviews of production records, batch records, OOS investigations, and APRs for all US-distributed drugs within expiry, perform risk assessments, and implement specific corrective and preventive actions. A written response detailing corrections and recurrence prevention is required within 15 working days. Failure to comply may result in FDA withholding approval of new applications and refusing admission of products into the U.S.

Company
Vital Laboratories Pvt Ltd Plant II
Inspection date
April 6, 2017
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • William Yang
  • Thomas J. Cosgrove
View Company Profile

ID · f662890f-f613-4bee-b298-88c9f7f5ac5e

Violation Codes5
FD&C Act 501(a)(2)(B)21 U.S.C. 381(a)(3)FD&C Act 801(a)(3)21 U.S.C. 356C(b)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Vital Laboratories Pvt Ltd Plant II
  • 483 - 2018-09-01September 1, 2018
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Vital Laboratories Pvt Ltd Plant II
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.